ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND) (ASCEND)

ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives.

The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatric intensive care unit. The second objective is to compare short and long-term patient outcomes in two groups of children: one group managed with a mechanical ventilation protocol that reserves the use of extracorporeal membrane oxygenation (ECMO) until protocol failure to another group supported on ECMO per usual care.

Study Overview

• Status: Recruiting
• Conditions: Extracorporeal Membrane Oxygenation; Acute Respiratory Distress Syndrome
• Intervention / Treatment: Device: ECMO support; Other: PROSpect protocolized therapies

Detailed Description

Decades after extracorporeal membrane oxygenation (ECMO) was first used to support children with severe pediatric acute respiratory distress syndrome (PARDS), pediatric intensivists lack both prospective studies of long-term outcomes in ECMO for PARDS and well-powered studies comparing the impact of ECMO initiation strategies on mortality and morbidity. While clinicians lack the equipoise necessary to randomize ECMO in dying children, there is uncertainty on if and when it is best to initiate ECMO to preserve survival, functioning, and quality of life. To determine if and when ECMO should be initiated in children with severe PARDS, it is necessary to compare the long-term outcomes in ECMO supported children to otherwise similar children who did not receive ECMO at the same threshold if at all.

An opportunity to address this question is provided by NHLBI-funded Prone and Oscillation Pediatric Clinical Trial (PROSpect) and the ECMO registry, Extracorporeal Life Support Organization (ELSO). PROSpect is an existing randomized clinical trial testing the impact of supine/prone positioning and conventional mechanical ventilation/high-frequency oscillatory ventilation on short and long-term clinical outcomes in 1,000 children with severe PARDS. PROSpect manages subjects with a rigorous protocol that reserves ECMO for protocol failure. The ELSO Registry includes children receiving usual care ECMO, initiated at the discretion of the intensivist.

ASCEND harmonizes PROSpect and ELSO data collection and prospectively measures functional status and quality of life via surveys in an additional 550 children with severe PARDS from ELSO sites. ASCEND measures children's abilities and quality of life when the child was in their normal state of health (just prior to being hospitalized), at discharge from the pediatric intensive care unit, and at 1-month, 3-months, 6-months, and 12-months after discharge from the pediatric intensive care unit. After enrollment of the usual care ECMO (in ELSO) and PROSpect's protocolized therapies (from the PROSpect clinical trial) is complete, then ASCEND will match similarly critically ill children based on their propensity to receive usual care ECMO.

ASCEND combines real-world observational data (from ELSO) and a randomized clinical trial (from PROSpect) to address two specific aims.

Aim 1: The study will test the hypotheses that one year after children receive usual care ECMO for PARDS, there will be a decline in long-term functional status and health-related quality of life as well as an increase in the proportion of children receiving respiratory support.

Aim 2: The study will test the hypotheses that 90-day mortality, one-year functional status, and one-year health-related quality of life are not equivalent for children with usual care ECMO (in ELSO) and PROSpect's protocolized therapies.

Protocol change in November 2021:

Inclusion criteria: Extend the window between intubation and ECMO cannulation from 120 hours to 168 hours.

Exclusion criteria: Remove active air leak, critical airway, and facial surgery/trauma within the last 2 weeks.

Protocol change in October 2022:

Inclusion criteria:

1. Extended the age range from 14 days - 17 years to 14 days - 20 years of age.
2. Extended the window between intubation and ECMO cannulation from 168 hours to 240 hours.

• Study Type: Observational
• Enrollment (Estimated): 550

Contacts and Locations

• Study Contact: Name: Kelli McDonough, MS; Phone Number: 734-232-1998; Email: kellimcd@umich.edu

Study Locations

• Australia
  • Melbourne, Australia, VIC 3052
    • Recruiting
    • The Royal Children's Hospital Melbourne
    • Contact: Warwick Butt; Phone Number: +61 3 9345 5522; Email: warwick.butt@rch.org.au
    • Principal Investigator: Warwick Butt, MD
  • Perth, Australia, WA 6009
    • Recruiting
    • Perth Children's Hospital
    • Contact: Simon Erickson; Phone Number: +61 8 6456 2222; Email: simon.erickson@health.wa.gov.au
    • Principal Investigator: Simon Erickson, MD
  • South Brisbane, Australia, QLD 4101
    • Recruiting
    • Queensland Children's Hospital
    • Contact: Adrian Mattke; Phone Number: 61 7 3068 1111; Email: adrian.mattke@health.qld.gov.au
    • Principal Investigator: Adrian Mattke, MD
  • Westmead, Australia, NSW 2145,
    • Recruiting
    • The Children's Hospital at Westmead
    • Contact: Nithesh Singhal; Phone Number: +61 2 7825 0000; Email: nitesh.singhal@health.nsw.gov.au
    • Principal Investigator: Nitesh Singhal, MD
• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6G 2B7
      • Recruiting
      • Stollery Children's Hospital
      • Contact: Laurance Lequier; Phone Number: +1 780-407-8822; Email: Laurance.Lequier@albertahealthservices.ca
      • Principal Investigator: Laurance Lequier, MD
  • Ontario
    • Toronto, Ontario, Canada, M5G 1E8
      • Recruiting
      • The Hospital for Sick Children
      • Contact: Anne Marie Guerguerian; Phone Number: +1 416-813-1500; Email: anne-marie.guerguerian@sickkids.ca
      • Principal Investigator: Anne-Marie Guerguerian, MD
• Chile
  • Santiago, Chile, 8331150
    • Recruiting
    • Pontificia Universidad
    • Contact: Javier Kattan, MD; Phone Number: +56 2 2633 2051; Email: kattan@med.puc.cl
    • Principal Investigator: Javier Kattan, MD
    • Principal Investigator: Andres Castillo, MD
• Colombia
  • Floridablanca, Colombia, 681004
    • Recruiting
    • Fundacion Cardiovascular de Colombia
    • Contact: Leonardo Salazar; Phone Number: +57 607 6399292; Email: demotucordis@gmail.com
    • Principal Investigator: Leonardo Salazar, MD
• Italy
  • Genoa, Italy, 16147
    • Recruiting
    • Istituto Giannina Gaslini
    • Contact: Andrea Moscatelli; Phone Number: +39 010 56361; Email: andreamoscatelli@me.com
    • Principal Investigator: Andrea Moscatelli
• New Zealand
  • Aukland
    • Grafton, Aukland, New Zealand, 1023
      • Recruiting
      • Starship Children's Hospital
      • Contact: John Beca; Phone Number: +64 9 367 0000; Email: johnbeca@adhb.govt.nz
      • Principal Investigator: John Beca
• Portugal
  • Lisbon, Portugal, 1649-028
    • Recruiting
    • Hospital de Santa Maria
    • Contact: Francisco Abecasis; Phone Number: +351 21 780 5000; Email: francisco@abecasis.name
    • Principal Investigator: Francisco Abecasis
• Spain
  • Barcelona, Spain, 08035
    • Recruiting
    • Children's Hospital and Vall d' Hebron Women's Hospital
    • Contact: Joan Balcells Ramirez; Phone Number: +34 934 89 30 00; Email: joanbalcells@me.com
    • Principal Investigator: Joan Balcells Ramirez
  • Barcelona, Spain, 08950
    • Recruiting
    • Sant Joan De Deu Barcelona Hospital
    • Contact: Susana Segura Matute; Phone Number: +34 932 53 21 00; Email: ssegura@sjdhospitalbarcelona.org
    • Principal Investigator: Susana Segura Matute
  • Madrid, Spain, 28007
    • Recruiting
    • Hospital Gregorio Marañon
    • Contact: Laura Butragueno Laiseca; Phone Number: +34 915 86 80 00; Email: laura.butragueno@salud.madrid.org
    • Principal Investigator: Laura Butragueno Laiseca
    • Sub-Investigator: Amelia Sanchez Galindo
• Sweden
  • Stockholm, Sweden, 17176
    • Recruiting
    • ECMO Centrum Karolinska
    • Contact: Lars Broman; Phone Number: +46 8 123 780 50; Email: lars.broman@sll.se
    • Principal Investigator: Lars Broman
• United Kingdom
  • Glasgow, United Kingdom, G51 4FT
    • Recruiting
    • Royal Hospital for Children
    • Contact: Mark Davidson; Phone Number: +44 141 201 0000; Email: mark.davidson3@ggc.scot.nhs.uk
    • Principal Investigator: Mark Davidson
  • Leicester, United Kingdom, LE3 9QP
    • Recruiting
    • Leicester Children's Hospital
    • Contact: Claire Westrope; Phone Number: +44 300 303 1573; Email: claire.westrope@uhl-tr.nhs.uk
    • Principal Investigator: Claire Westrope
  • Liverpool, United Kingdom, L12 2AP
    • Recruiting
    • Alder Hey Children's Hospital
    • Contact: Marie Horan; Phone Number: +44 151 228 4811; Email: marie.horan@alderhey.nhs.uk
    • Principal Investigator: Marie Horan
  • London, United Kingdom, WC1N 3JH
    • Recruiting
    • Great Ormond Street Hospital for Children
    • Contact: Timothy Thiruchelvam; Phone Number: +44 20 7405 9200; Email: timothy.thiruchelvam@gosh.nhs.uk
    • Principal Investigator: Timothy Thiruchelvam
  • London, United Kingdom, SE1 7EH
    • Recruiting
    • Evelina London Children's Hospital
    • Contact: Jonathan Lillie; Phone Number: +44 20 7188 7188; Email: jonathan.lillie@gstt.nhs.uk
    • Principal Investigator: Jonathan Lillie
  • London, United Kingdom, SW3 6NP
    • Recruiting
    • Royal Brompton Hospital
    • Contact: Justin Wang; Phone Number: +44 20 7352 8121; Email: Q.Wang@rbht.nhs.uk
    • Principal Investigator: Justin Wang
  • Newcastle upon Tyne, United Kingdom, NE77DN
    • Recruiting
    • Freeman Hospital
    • Contact: Judit Llevadias; Phone Number: +44 191 233 6161; Email: judit.llevadias@nhs.uk
    • Principal Investigator: Judit Llevadias
  • Southampton, United Kingdom, SO16 6YD
    • Recruiting
    • Southampton Children's Hospital
    • Contact: Vanessa Stanley; Phone Number: +44 023 8077 7222
    • Principal Investigator: Vanessa Stanley
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35233
      • Recruiting
      • Children's of Alabama
      • Contact: Robert Richter, MD; Phone Number: (205) 638-9100; Email: rrichter@peds.aub.edu
      • Principal Investigator: Robert Richter, MD
  • Arizona
    • Phoenix, Arizona, United States, 85016
      • Recruiting
      • Phoenix Children's Hospital
      • Contact: Erin Kreml, MD; Phone Number: (602) 933-1000; Email: ekreml@phoenixchildrens.com
      • Principal Investigator: Erin Kreml, MD
  • Arkansas
    • Little Rock, Arkansas, United States, 72202
      • Recruiting
      • Arkansas Children's Hospital
      • Contact: Matthew Malone, MD; Phone Number: (501) 441-3453; Email: MPMalone@uams.edu
      • Principal Investigator: Matthew Malone, MD
  • California
    • Loma Linda, California, United States, 92354
      • Recruiting
      • Loma Linda University Children's Hospital
      • Contact: Merrick Lopez, MD; Phone Number: (909) 558-8000; Email: MLopez@llu.edu
      • Principal Investigator: Merrick Lopez, MD
    • Los Angeles, California, United States, 90095
      • Recruiting
      • UCLA Mattel Children's Hospital
      • Contact: Neeraj Srivastava, MD; Phone Number: (310) 825-9111; Email: neerajsrivastava@mednet.ucla.edu
      • Principal Investigator: Neeraj Srivastava, MD
    • Madera, California, United States, 93636
      • Recruiting
      • Valley Children's Hospital
      • Contact: Harry Kallas, MD; Phone Number: (559) 353-3000; Email: HKallas@valleychildrens.org
      • Principal Investigator: Harry Kallas, MD
    • Oakland, California, United States, 94609
      • Recruiting
      • UCSF Benioff Children's Hospital Oakland
      • Contact: Mandeep Chadha, MD; Phone Number: (510) 428-3000; Email: Mandeep.Chadha@ucsf.edu
      • Principal Investigator: Mandeep Chadha, MD
    • Orange, California, United States, 92868
      • Recruiting
      • Children's Hospital of Orange County
      • Principal Investigator: Adam Schwarz, MD
      • Contact: Adam Schwarz, MD; Phone Number: (714) 997-3000; Email: ASchwarz@choc.org
    • Palo Alto, California, United States, 94304
      • Recruiting
      • Lucile Packard Children's Hospital Stanford
      • Contact: Timothy Cornell, MD; Phone Number: (650) 497-8000; Email: tcornell@stanford.edu
      • Principal Investigator: Timothy Cornell, MD
    • San Francisco, California, United States, 94158
      • Recruiting
      • UCSF Benioff Children's Hospital - San Francisco
      • Contact: Shan Ward, MD; Phone Number: (415) 476-1000; Email: shan.ward@ucsf.edu
      • Principal Investigator: Shan Ward, MD
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Recruiting
      • Children's Hospital Colorado
      • Principal Investigator: John Kim, MD
      • Contact: John Kim, MD; Phone Number: 720-777-1234; Email: John.Kim@childrenscolorado.org
  • Connecticut
    • Hartford, Connecticut, United States, 06106
      • Recruiting
      • Connecticut Children's Medical Center
      • Contact: Allison Cowl, MD; Phone Number: (860) 545-9000; Email: acowl@connecticutchildrens.org
      • Principal Investigator: Allison Cowl, MD
    • New Haven, Connecticut, United States, 06511
      • Recruiting
      • Yale New Haven Children's Hospital
      • Contact: Josep Panisello, MD; Phone Number: 203-688-4242; Email: josep.panisello@yale.edu
      • Principal Investigator: Josep Panisello, MD
  • Delaware
    • Wilmington, Delaware, United States, 19803
      • Recruiting
      • Nemours Children's Hospital, Delaware
      • Contact: Marisa Meyer, MD; Phone Number: (302) 651-4200; Email: Marisa.Meyer@nemours.org
      • Principal Investigator: Marisa Meyer, MD
  • Florida
    • Gainesville, Florida, United States, 32608
      • Recruiting
      • UF Health Shands Children's Hospital
      • Contact: Kourtney Guthrie, MD; Phone Number: (352) 733-0111; Email: ksnodgrass@ufl.edu
      • Principal Investigator: Kourtney Guthrie, MD
    • Miami, Florida, United States, 33155
      • Withdrawn
      • Nicklaus Children's Hospital
    • Orlando, Florida, United States, 32827
      • Recruiting
      • Nemours Children's Hospital, Florida
      • Contact: Timothy Maul, MD; Phone Number: (407) 567-4000; Email: timothy.maul@nemours.org
      • Principal Investigator: Timothy Maul, MD
    • Orlando, Florida, United States, 32806
      • Recruiting
      • Orlando Health Arnold Palmer Hospital for Children
      • Contact: Nicole Slone, MD; Phone Number: (407) 649-9111; Email: Nicole.Slone@orlandohealth.com
      • Principal Investigator: Nicole Slone, MD
  • Georgia
    • Atlanta, Georgia, United States, 30342
      • Recruiting
      • Children's Healthcare of Atlanta
      • Contact: Heather Viamonte, MD; Phone Number: (404) 785-5437; Email: heather.chandler@choa.org
      • Principal Investigator: Heather Viamonte, MD
  • Hawaii
    • Honolulu, Hawaii, United States, 96826
      • Recruiting
      • Kapi'olani Medical Center for Women & Children
      • Contact: Len Tanaka, MD; Phone Number: (808) 983-6000; Email: lent@hawaii.edu
      • Principal Investigator: Len Tanaka, MD
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Recruiting
      • Ann & Robert H. Lurie Children's Hospital of Chicago
      • Contact: Bria Coates, MD; Phone Number: (312) 227-4000; Email: b-coates@northwestern.edu
      • Principal Investigator: Bria Coates, MD
    • Chicago, Illinois, United States, 60637
      • Recruiting
      • Comer Children's Hospital
      • Contact: Karen Fauman, MD; Phone Number: (888) 824-0200; Email: krfauman@pds.bsd.uchigago.edu
      • Principal Investigator: Karen Fauman, MD
    • Peoria, Illinois, United States, 61637
      • Recruiting
      • OSF Healthcare Children's Hospital of Illinois
      • Contact: Agnieszka Kulikowska, MD; Phone Number: 309-655-7171; Email: akmd@uic.edu
      • Principal Investigator: Agnieszka Kulikowska, MD
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Recruiting
      • Riley Hospital for Children
      • Contact: Matt Friedman, MD; Phone Number: (317) 944-5000; Email: friedmml@iu.edu
      • Principal Investigator: Matthew Friedman, MD
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • Recruiting
      • University of Iowa Health Care Stead Family Children's Hospital
      • Principal Investigator: Kari Wellnitz, MD
      • Contact: Kari Wellnitz, MD; Phone Number: (888) 573-5437; Email: kari-wellnitz@uiowa.edu
  • Kentucky
    • Louisville, Kentucky, United States, 40202
      • Recruiting
      • Norton Children's Hospital
      • Contact: Deanna Tzanetos, MD; Phone Number: (502) 629-6000; Email: deanna.tzanetos@louisville.edu
      • Principal Investigator: Deanna Tzanetos, MD
  • Louisiana
    • Shreveport, Louisiana, United States, 71103
      • Recruiting
      • Ochsner LSU Health Shreveport
      • Contact: Steve Conrad, MD; Phone Number: (318) 626-0000; Email: SConrad@lsuhsc.edu
      • Principal Investigator: Steven Conrad, MD
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • Recruiting
      • Johns Hopkins Children's Center
      • Contact: Mela Bembea, MD; Phone Number: (410) 955-5000; Email: mbembea1@jhmi.edu
      • Principal Investigator: Mela Bembea, MD
    • Baltimore, Maryland, United States, 21201
      • Withdrawn
      • University of Maryland Children's Hospital
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Recruiting
      • Boston Children's Hospital
      • Contact: Sally Vitali, MD; Phone Number: 617-355-6000; Email: Sally.Vitali@childrens.harvard.edu
      • Principal Investigator: Sally Vitale, MD
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • Recruiting
      • University of Michigan - Mott Children's Hospital
      • Contact: Kelli McDonough, MS; Phone Number: 734-232-1998; Email: kellimcd@umich.edu
      • Principal Investigator: Ryan Barbaro, MD
    • Detroit, Michigan, United States, 48201
      • Recruiting
      • Children's Hospital of Michigan
      • Contact: Mina Hafzala, MD; Phone Number: (313) 745-5437; Email: MHafzala@dmc.org
      • Principal Investigator: Mina Hafzala, MD
    • Grand Rapids, Michigan, United States, 49503
      • Recruiting
      • Helen DeVos Children's Hospital
      • Contact: Elizabeth Rosner, MD; Phone Number: (616) 391-9000; Email: Elizabeth.Rosner@helendevoschildrens.org
      • Principal Investigator: Elizabeth Rosner, MD
  • Minnesota
    • Minneapolis, Minnesota, United States, 55404
      • Recruiting
      • Children's Minnesota Hospital
      • Contact: Mark Eikenberry, MD; Phone Number: (612) 813-6000; Email: Mark.Eikenberry@childrensmn.org
      • Principal Investigator: Mark Eikenberry, MD
    • Minneapolis, Minnesota, United States, 55454
      • Withdrawn
      • M Health Fairview Masonic Children's Hospital
    • Rochester, Minnesota, United States, 55902
      • Recruiting
      • Mayo Eugenio Litta Children's Hospital
      • Contact: Jeffrey Weatherhead, MD; Phone Number: (507) 255-5123; Email: Weatherhead.Jeffrey@mayo.edu
      • Principal Investigator: Jeffrey Weatherhead, MD
  • Missouri
    • Kansas City, Missouri, United States, 64108
      • Recruiting
      • Children's Mercy
      • Contact: Asdis Wagner, MD; Phone Number: (866) 512-2168; Email: dfwagner@cmh.edu
      • Principal Investigator: Asdis Wagner, MD
    • St Louis, Missouri, United States, 63110
      • Recruiting
      • St. Louis Children's Hospital
      • Contact: Ahmed Said, MD; Phone Number: (314) 454-6000; Email: said_a@wustl.edu
      • Principal Investigator: Ahmed Said, MD
    • St Louis, Missouri, United States, 63104
      • Recruiting
      • Cardinal Glennon Children's Hospital
      • Contact: Erik Madsen, MD; Phone Number: (314) 577-5600; Email: erik.madsen@ssmhealth.com
      • Principal Investigator: Erik Madsen, MD
  • Nebraska
    • Omaha, Nebraska, United States, 68114
      • Recruiting
      • Children's Nebraska
      • Contact: Santosh Kaipa, MD; Phone Number: (402) 955-5400; Email: skaipa@childrensnebraska.org
      • Principal Investigator: Santosh Kaipa, MD
  • New Mexico
    • Albuquerque, New Mexico, United States, 87106
      • Recruiting
      • UNM Children's Hospital
      • Contact: Senan Hadid, MD; Phone Number: (505) 272-2111; Email: shadid@salud.umn.edu
      • Principal Investigator: Senan Hadid, MD
  • New York
    • Buffalo, New York, United States, 14203
      • Recruiting
      • John R. Oishei Children's Hospital
      • Principal Investigator: Ryan Breuer, MD
      • Contact: Ryan Breuer, MD; Phone Number: (716) 323-2000; Email: rbreuer@upa.chob.edu
    • New York, New York, United States, 10016
      • Recruiting
      • Hassenfeld Children's Hospital at NYU Langone
      • Contact: Arun Chopra, MD; Phone Number: (646) 929-7970; Email: arun.chopra@nyulangone.org
      • Principal Investigator: Arun Chopra, MD
    • New York, New York, United States, 10032
      • Recruiting
      • NewYork-Presbyterian Morgan Stanley Children's Hospital
      • Contact: Eva Cheung, MD; Phone Number: (212) 305-5437; Email: ec2335@cumc.columbia.edu
      • Principal Investigator: Eva Cheung, MD
    • New York, New York, United States, 10065
      • Recruiting
      • NewYork-Presbyterian Komansky Children's Hospital
      • Contact: Umesh Joashi, MD; Phone Number: (212) 746-5454; Email: ucj4001@med.cornell.edu
      • Principal Investigator: Umesh Joashi, MD
    • Queens, New York, United States, 11040
      • Recruiting
      • Cohen Children's Medical Center
      • Principal Investigator: Todd Sweberg, MD
      • Contact: Todd Sweberg, MD; Phone Number: (833) 462-6436; Email: tsweberg@northwell.edu
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27514
      • Recruiting
      • N.C. Children's Hospital
      • Contact: Katherine Clement, MD; Phone Number: (984) 974-1000; Email: katherine_clement@med.unc.edu
      • Principal Investigator: Katherine Clement, MD
    • Durham, North Carolina, United States, 27705
      • Recruiting
      • Duke Children's Hospital & Health Center
      • Contact: Palen Mallory, MD; Phone Number: (919) 668-4000; Email: palen.powelson@duke.edu
      • Principal Investigator: Palen Mallory, MD
    • Winston-Salem, North Carolina, United States, 27157
      • Recruiting
      • Atrium Health Wake Forest Baptist | Brenner Children's Hospital
      • Contact: Alan Woodruff, MD; Phone Number: (336) 713-4500; Email: agwoodru@wakehealth.edu
      • Principal Investigator: Alan Woodruff, MD
  • Ohio
    • Akron, Ohio, United States, 44308
      • Recruiting
      • Akron Children's Hospital
      • Contact: Patricia Raimer, MD; Phone Number: (330) 543-8352; Email: PRaimer@akronchildrens.org
      • Principal Investigator: Patricia Raimer, MD
    • Cincinnati, Ohio, United States, 45229
      • Recruiting
      • Cincinnati Children's Hospital Medical Center
      • Principal Investigator: Ranjit Chima, MD
      • Contact: Ranjit Chima, MD; Phone Number: (513) 636-4200; Email: Ranjit.Chima@cchmc.org
    • Cleveland, Ohio, United States, 44106
      • Recruiting
      • Cleveland Clinic Children's Hospital
      • Contact: Karen Lidsky, MD; Phone Number: (216) 444-5437; Email: lidskyk@ccf.org
      • Principal Investigator: Karen Lidsky, MD
    • Columbus, Ohio, United States, 43215
      • Recruiting
      • Nationwide Children's Hospital
      • Contact: Joshua Frazier, MD; Phone Number: (614) 722-5650; Email: joshua.frazier@nationwidechildrens.org
      • Principal Investigator: Joshua Frazier, MD
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
      • Recruiting
      • Oklahoma Children's Hospital OU Health
      • Principal Investigator: Christine Allen, MD
      • Contact: Christine Allen, MD; Phone Number: (405) 271-5437; Email: Christine-Allen@ouhsc.edu
  • Oregon
    • Portland, Oregon, United States, 97239
      • Recruiting
      • OHSU Doernbecher Children's Hospital
      • Contact: Amit Mehta, MD; Phone Number: (503) 346-0640; Email: mehtaa@ohsu.edu
      • Principal Investigator: Amit Mehta, MD
  • Pennsylvania
    • Hershey, Pennsylvania, United States, 17033
      • Recruiting
      • Penn State Health Children's Hospital
      • Principal Investigator: Elizabeth Kerris, MD
      • Contact: Elizabeth Kerris, MD; Phone Number: (800) 243-1455; Email: ekerris@pennstatehealth.psu.edu
    • Philadelphia, Pennsylvania, United States, 19104
      • Recruiting
      • Children's Hospital of Philadelphia
      • Contact: Adam Himebaugh, MD; Phone Number: (215) 590-1000; Email: himebaugha@chop.edu
      • Principal Investigator: Adam Himebaugh, MD
    • Pittsburgh, Pennsylvania, United States, 15224
      • Recruiting
      • UPMC Children's Hospital of Pittsburgh
      • Contact: Nahmah Kim-Campbell, MD; Phone Number: (412) 692-5325; Email: nahmah.kim-campbell@chp.edu
      • Principal Investigator: Nahmah Kim-Campbell, MD
  • Rhode Island
    • Providence, Rhode Island, United States, 02903
      • Recruiting
      • Hasbro Children's
      • Contact: Ranna Rozenfeld, MD; Phone Number: (401) 444-4000; Email: ranna_rozenfeld@brown.edu
      • Principal Investigator: Ranna Rozenfeld, MD
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • Recruiting
      • MUSC Shawn Jenkins Children's Hospital
      • Contact: Elise Zivick, MD; Phone Number: (843) 792-2300; Email: emrath@musc.edu
      • Principal Investigator: Elizabeth Zivick, MD
  • South Dakota
    • Sious Falls, South Dakota, United States, 57105
      • Recruiting
      • Sanford Children's Hospital
      • Contact: Jody Huber, MD; Phone Number: (605) 312-1000; Email: jody.huber@sanfordhealth.org
      • Principal Investigator: Jody Huber, MD
  • Tennessee
    • Memphis, Tennessee, United States, 38103
      • Recruiting
      • Le Bonheur Children's Hospital
      • Contact: Hitesh Sandhu, MD; Phone Number: (901) 287-5437; Email: hsandhu@uthsc.edu
      • Principal Investigator: Hitesh Sandhu, MD
    • Nashville, Tennessee, United States, 37232
      • Recruiting
      • Monroe Carell Jr. Children's Hospital at Vanderbilt
      • Contact: Kevin Johnson, MD; Phone Number: (615) 936-1000; Email: k.johnson@vumc.org
      • Principal Investigator: Kevin Johnson, MD
  • Texas
    • Austin, Texas, United States, 78723
      • Recruiting
      • Dell Children's Medical Center
      • Contact: Samantha Dallefeld, MD; Phone Number: (512) 324-0000; Email: samantha.dallefeld@ascension.org
      • Principal Investigator: Samantha Dallefeld, MD
    • Dallas, Texas, United States, 75235
      • Recruiting
      • Children's Medical Center Dallas
      • Contact: Archana Dhar, MD; Phone Number: (214) 456-7000; Email: archana.dhar@UTSouthwestern.edu
      • Principal Investigator: Archana Dhar, MD
    • Dallas, Texas, United States, 75230
      • Recruiting
      • Medical City Children's Hospital
      • Contact: JJ Fanning, MD; Phone Number: (972) 566-7000; Email: jfanning@pacant.com
      • Principal Investigator: JJ Fanning, MD
    • Houston, Texas, United States, 77030
      • Recruiting
      • Texas Children's Hospital
      • Contact: Andrea Ontaneda, MD; Phone Number: (832) 824-1000; Email: amontan1@texaschildrens.org
      • Principal Investigator: Andrea Ontaneda, MD
    • Houston, Texas, United States, 77030
      • Recruiting
      • Children's Memorial Hermann Hospital
      • Contact: Sonia Labarinas, MD; Phone Number: (713) 704-5437; Email: sonia.labarinas@uth.tmc.edu
      • Principal Investigator: Sonia Labarinas, MD
    • San Antonio, Texas, United States, 78229
      • Recruiting
      • University Health Women's & Children's Hospital
      • Contact: Veronica Armijo-Garcia, MD; Phone Number: (210) 358-4000; Email: mirelesv@uthscsa.edu
      • Principal Investigator: Veronica Armijo-Garcia, MD
  • Utah
    • Salt Lake City, Utah, United States, 84113
      • Recruiting
      • Primary Children's Hospital
      • Contact: Anna Hubbard, MD; Phone Number: (801) 662-1000; Email: anna.hubbard@hsc.utah.edu
      • Principal Investigator: Anna Hubbard, MD
  • Virginia
    • Charlottesville, Virginia, United States, 22903
      • Recruiting
      • UVA Children's Hospital
      • Contact: Gary Fang, MD; Phone Number: 434.924.5321; Email: GYF2N@hscmail.mcc.virginia.edu
      • Principal Investigator: Gary Fang, MD
    • Falls Church, Virginia, United States, 22042
      • Recruiting
      • Inova L.J. Murphy Children's Hospital
      • Contact: Jeremy Lamkin, MD; Phone Number: (703) 776-4002; Email: Jeremy.Lamkin@inova.org
      • Principal Investigator: Jeremy Lamkin, MD
    • Richmond, Virginia, United States, 23219
      • Withdrawn
      • Children's Hospital of Richmond at VCU
  • Washington
    • Seattle, Washington, United States, 98105
      • Recruiting
      • Seattle Children's Hospital
      • Contact: Thomas Brogan, MD; Phone Number: (206) 987-2000; Email: thomas.brogan@seattlechildrens.org
      • Principal Investigator: Thomas Brogan, MD
  • Wisconsin
    • Madison, Wisconsin, United States, 53792
      • Recruiting
      • UW Health American Family Children's Hospital
      • Contact: Charlie Bergstrom, MD; Phone Number: (608) 263-7337; Email: cpbergstrom@wisc.edu
      • Principal Investigator: Charlie Bergstrom, MD
    • Milwaukee, Wisconsin, United States, 53226
      • Recruiting
      • Children's Wisconsin
      • Contact: Adam Szadkowski, MD; Phone Number: (414) 266-2000; Email: aszadkowski@mcw.edu
      • Principal Investigator: Adam Szadkowski, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 weeks to 17 years (Child, Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The study population comes from pediatric patients hospitalized for respiratory distress requiring intubation and ECMO. Namely, children are eligible if they have moderate to severe PARDS, meet inclusion criteria and do not have the exclusion criteria listed below under exclusion criteria. Children in ELSO's usual care ECMO cohort also cannot be enrolled in PROSpect, and they must have respiratory ECMO initiated at an ELSO site within 10 days of intubation.

Description

Inclusion Criteria:

• Time between intubation and ECMO cannulation is less than 240 hours (10 days)
• ECMO support type is respiratory (VV or VA cannulation)
• Chest radiograph with bilateral lung disease
• Moderate or severe pediatric ARDS as measured by oxygenation index or oxygen saturation index after intubation and prior to ECMO cannulation:

One OI ≥ 16 or Two OIs ≥ 12 and ≤ 16 at least four hours apart or Two OSIs ≥ 10 at least four hours apart or One OI ≥ 12 and ≤ 16 and One OSI ≥ 10 at least four hours apart

Exclusion Criteria:

• Previously enrolled in PROSpect
• Perinatal related lung disease
• Congenital diaphragmatic hernia or congenital/acquired diaphragm paralysis
• Respiratory failure caused by cardiac failure or fluid overload
• Cyanotic congenital heart disease
• Cardiomyopathy
• Primary pulmonary hypertension (PAH)
• Unilateral lung disease
• Intubated for status asthmaticus
• Obstructive airway disease
• Bronchiolitis obliterans
• Post hematopoietic stem cell transplant
• Post lung transplant
• Home ventilator dependent
• Neuromuscular respiratory failure
• Head trauma: (managed with hyperventilation)
• Intracranial bleeding
• Unstable spine, femur or pelvic fractures
• Acute abdominal process/open abdomen
• Family/medical team have decided to not provide full support
• Enrolled in interventional clinical trial: not approved for co-enrollment; does not include cancer protocols.
• Known pregnancy

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Usual care ECMO Cohort; The cohort will be comprised of 550 patients, aged 14 days to 20 years, who go on extracorporeal membrane oxygenation (ECMO) support due to pediatric acute respiratory distress syndrome (PARDS) at physician discretion. Patients with qualifying PARDS must have one oxygenation index (OI) ≥ 16 or two OIs 12 ≥ to < 16 (at least 4 hours apart) or two oxygenation saturation indexes (OSIs) ≥ 10 (at least 4 hours apart) or one OI 12 ≥ to < 16 and one OSI > 10 (at least 4 hours apart) Subjects must be on mechanical ventilation for less than 240 hours (10 days) prior to cannulation. These measures must be after endotracheal intubation and before ECMO start. Chest radiograph prior to ECMO must show bilateral lung disease. Subjects cannulated on ECMO for no more than 96 hours prior to gaining consent.	Device: ECMO support; ECMO prescribed by treating physicians for respiratory support in the setting of PARDS.
PROSpect protocolized therapies cohort; The cohort will be comprised of 1000 patients, aged 14 days to 20 years, who are endotracheally intubated for PARDS. Patients with qualifying PARDS must have one oxygenation index (OI) ≥ 16 or two OIs 12 ≥ to < 16 (at least 4 hours apart) or two oxygenation saturation indexes (OSIs) ≥ 10 (at least 4 hours apart) or one OI 12 ≥ to < 16 and one OSI > 10 (at least 4 hours apart). These measures must be after endotracheal intubation. Chest radiograph must show bilateral lung disease. Patient must be enrolled in a clinical trial Prone and Oscillation Pediatric Clinical Trial (PROSpect) NCT01515787 which is distinct from ASCEND. PROSpect is a response adaptive randomized clinical trial, testing the impact of supine/prone positioning and conventional mechanical ventilation/high-frequency oscillatory ventilation on short and long-term clinical outcomes in children with severe PARDS. PROSpect manages severe PARDS subjects using a rigorous protocol that reserves ECMO for protocol failure.	Other: PROSpect protocolized therapies; PROSpect is testing the impact of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV) on clinical outcomes in 1,000 children with severe PARDS. PROSpect manages severe PARDS subjects using a protocol that reserves ECMO for protocol failure. The CMV group targets an exhaled tidal volume of 5-7mL/kg of ideal body weight and a peak inspiratory pressure <28 cm of H2O. The positive end expiratory pressure (PEEP) and FiO2 are titrated by a PEEP-FiO2 titration grid. The HFOV group titrates the mean airway pressure to target a FiO2 < 0.5 and a goal hemoglobin oxygen saturation of 88-92%. The frequency is titrated between 8-12 Hz and amplitude from 60-90 to achieve a goal pH of 7.15-7.30. Ventilation protocols are implemented until 28 days or extubation. Children randomized to the prone positioning will remain prone for at least 16 consecutive hours per day. Children randomized to supine positioning group remain supine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
All-cause mortality at hospital discharge or 90-days	This primary comparative short-term outcome is measured among both usual care ECMO and Prone and Oscillation Pediatric Clinical Trial (PROSpect) protocolized therapy groups. The outcome compares the 90-day mortality for matched children in the two groups. The endpoint is 90 days after the day of illness on which patients from the two cohorts are matched or hospital discharge.	90 days after the day of illness on which patients from the two cohorts are matched
Change in functional status	This primary natural history outcome is measured among usual care extracorporeal membrane oxygenation (ECMO) patients. This outcome is the change in functional status as measured at baseline and 12 months after pediatric intensive care unit (PICU) discharge. The instrument is the functional status scale score. The baseline measure will be made within 96 hours of ECMO initiation and reflect patient's status in the week prior to ECMO. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction); total scores range from 6 to 30 with higher scores reflecting worse functioning.	baseline and 1 year after pediatric intensive care unit discharge
Change in health-related quality of life	This primary natural history outcome is measured among usual care ECMO patients. This outcome is the change in the health-related quality of life as measured at baseline and 12 months after PICU discharge. The instrument is the age-appropriate Version 4.0 Pediatric Quality of Life Inventory (PedsQL 4.0) generic core scales for acute illness. PedsQL 4.0 Generic Core Scales and Infant Scales - Acute Version are parent proxy-report scales. The scales ranges from 0 to 100, with higher scores indicating fewer problems. PedsQL 4.0 Generic Core Scales is a 23-item scale with 4 domains: physical functioning, emotional functioning, social functioning, and school functioning. The PedsQL Infant Scales consist of 36-45 questions, depending on age, with 5 domains: physical functioning, physical symptoms, emotional functioning, social functioning, and cognitive functioning.	baseline and 1 year after pediatric intensive care unit discharge
The proportion of children with a new morbidity	This primary natural history outcome is measured among usual care ECMO patients. A new morbidity is defined as a change in the functional status scale score instrument by 3 or more, as previously described. This outcome will report the proportion of children who acquire a new morbidity as measured at baseline and 12 months after PICU discharge. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction); total scores range from 6 to 30 with higher scores reflecting worse functioning.	baseline and 1 year after pediatric intensive care unit discharge
Comparative change in one-year functional status	This primary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. The outcome compares the change in the functional status as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the functional status scale score. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction); total scores range from 6 to 30 with higher scores reflecting worse functioning.	baseline and 1 year after pediatric intensive care unit discharge
Comparative change in one-year health-related quality of life	This primary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. The outcome compares the change in the health-related quality of life as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the change in the age-appropriate PedsQL 4.0 generic core scales for acute illness. PedsQL 4.0 Generic Core Scales and Infant Scales - Acute Version are parent proxy-report scales. The scales ranges from 0 to 100, with higher scores indicating fewer problems. PedsQL 4.0 Generic Core Scales is a 23-item scale with 4 domains: physical functioning, emotional functioning, social functioning, and school functioning. The PedsQL Infant Scales consist of 36-45 questions, depending on age, with 5 domains: physical functioning, physical symptoms, emotional functioning, social functioning, and cognitive functioning.	baseline and 1 year after pediatric intensive care unit discharge

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference between groups in intracranial bleeding or ischemic stroke	This secondary comparative short-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. This outcome compares the difference in the proportion of matched children who suffer a new intracranial hemorrhage or ischemic stroke (recognized on radiologic imaging) between the two groups.	28 days after day in illness patients are matched or during hospitalization
Difference between groups in pneumothorax	This secondary comparative short-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. This outcome compares the difference in the proportion of matched children who suffer a pulmonary complication of a new pneumothorax at 28 days between children in the two groups.	28 days after day in illness patients are matched or during hospitalization
Change in pediatric overall performance category	This secondary natural history outcome is measured among usual care ECMO patients. The outcome is the change in the pediatric overall performance category measured at baseline and 12 months after PICU discharge. The instrument is the pediatric overall performance category. The Pediatric Overall Performance Category (POPC) quantifies impairments and functional morbidity. Scores range from 1 to 6 with 1: good, 2: mild disability, 3: moderate disability, 4: severe disability, 5: coma, and 6: brain death.	baseline and 1 year after pediatric intensive care unit discharge
Change in pediatric cerebral performance category	This secondary natural history outcome is measured among usual care ECMO patients. This outcome is the change in the pediatric cerebral performance category measured at baseline and 12 months after PICU discharge. The instrument is the pediatric cerebral performance category. The Pediatric Cerebral Performance Category (PCPC) quantifies cognitive impairments. Scores range from 1 to 6 with 1: good, 2: mild disability, 3: moderate disability, 4: severe disability, 5: coma, and 6: brain death.	baseline and 1 year after pediatric intensive care unit discharge
Change in breathing support	This secondary natural history outcome is measured among usual care ECMO patients. This outcome is the change in breathing support measured at baseline and 12 months after PICU discharge. The instrument is the respiratory subscale of the functional status scale score. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status with 6 domains. This measure of breathing support will rely on the FSS respiratory domain. The respiratory domain score ranges from 1 (normal) to 5 (very severe dysfunction).	baseline and 1 year after pediatric intensive care unit discharge
Change in the psychosocial component of health-related quality of life	This secondary natural history outcome is measured among usual care ECMO patients. This outcome is the change in the psychosocial component of health-related quality of life measured at baseline and 12 months after PICU discharge. The instrument is the age-appropriate psychosocial health summary score of the PedsQL 4.0 generic core scales for acute illness. PedsQL 4.0 Generic Core Scales and Infant Scales - Acute Version are parent proxy-report scales. The scales range from 0 to 100, with higher scores indicating fewer problems. The psychosocial component of the PedsQL 4.0 Generic Core Scales is composed of three of the four domains: emotional functioning, social functioning, and school functioning. The PedsQL Infant Scales psychosocial component is composed of three of the five domains: emotional functioning, social functioning, and cognitive functioning.	baseline and 1 year after pediatric intensive care unit discharge
Change in the physical component of health-related quality of life	This secondary natural history outcome is measured among usual care ECMO patients. The outcome is the change in the physical component of health-related quality of life measured at baseline and 12 months after PICU discharge. The instrument is the age-appropriate physical health summary score of the PedsQL 4.0 generic core scales for acute illness. PedsQL 4.0 Generic Core Scales and Infant Scales - Acute Version are parent proxy-report scales. The scales range from 0 to 100, with higher scores indicating fewer problems. The physical component of the PedsQL 4.0 Generic Core Scales is composed of one of the four domains: physical functioning. The PedsQL Infant Scales physical component is composed of two of the five domains: physical functioning and physical symptoms.	baseline and 1 year after pediatric intensive care unit discharge
Change in child fatigue	This secondary natural history outcome is measured among usual care ECMO patients. This outcome is the change in child fatigue measured at baseline and 12 months after PICU discharge. The instrument is the age-appropriate PedsQL fatigue scale for acute illness. The PedsQL™ Multi-dimensional Fatigue Scale - Acute Version is an 18-item scale that encompasses three domains: General Fatigue, Sleep/Rest Fatigue and Cognitive Fatigue. The scale ranges from 0 to 100, with higher scores indicating fewer problems and better health-related quality of life.	baseline and 1 year after pediatric intensive care unit discharge
Change in family impact of the child's health	This secondary natural history outcome is measured among usual care ECMO patients. This outcome is the change in child fatigue measured at baseline and 12 months after PICU discharge. The instrument is the age-appropriate PedsQL fatigue scale for acute illness. The PedsQL™ Family Impact Module - Acute Version is a 36-item scale that encompasses eight domains: Physical Functioning, Emotional Functioning, Social Functioning, Cognitive Functioning, Communication, Worry, Daily Activities, and Family Relationships. The scale ranges from 0 to 100, with higher scores indicating fewer problems.	baseline and 1 year after pediatric intensive care unit discharge
Change in one-year functional status of children suffering a neurologic injury	This secondary natural history outcome is measured among usual care ECMO patients. A neurologic injury is defined as a new intracranial hemorrhage or stroke recognized on radiologic imaging. This outcome will compare the change in functional status as measured at baseline and 12 months after PICU discharge between those children who suffered a neurologic injury to those who did not. The instrument is the functional status scale score. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction) with total scores ranging from 6 to 30.	baseline and 1 year after pediatric intensive care unit discharge
Comparative difference in the change in child fatigue	This secondary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. This outcome compares the change in child fatigue as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the age-appropriate PedsQL fatigue scale for acute illness. The PedsQL™ Multi-dimensional Fatigue Scale - Acute Version is an 18-item scale that encompasses three domains: General Fatigue, Sleep/Rest Fatigue and Cognitive Fatigue. The scale ranges from 0 to 100, with higher scores indicating fewer problems and better health-related quality of life.	baseline and 1 year after pediatric intensive care unit discharge
Comparative difference in the change in family impact of the child's health	This secondary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. This outcome compares the change in family impact of the child's health as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the PedsQL family impact module for acute illness. The PedsQL™ Family Impact Module - Acute Version is a 36-item scale that encompasses eight domains: Physical Functioning, Emotional Functioning, Social Functioning, Cognitive Functioning, Communication, Worry, Daily Activities, and Family Relationships. The scale ranges from 0 to 100, with higher scores indicating fewer problems.	baseline and 1 year after pediatric intensive care unit discharge
Comparative difference in the change in the psychosocial component of health-related quality of life	This secondary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. This outcome compares the change in the psychosocial component of health-related quality of life as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the age-appropriate psychosocial health summary score from PedsQL 4.0 generic core scales for acute illness. PedsQL 4.0 Generic Core Scales and Infant Scales - Acute Version are parent proxy-report scales. The scale ranges from 0 to 100, with higher scores indicating fewer problems. The psychosocial component of the PedsQL 4.0 Generic Core Scales is composed of three of the four domains: emotional functioning, social functioning, and school functioning. The PedsQL Infant Scales psychosocial component is composed of three of the five domains: emotional functioning, social functioning, and cognitive functioning.	baseline and 1 year after pediatric intensive care unit discharge
Comparative difference in the in change in the physical component of health-related quality of life	This secondary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. This outcome compares the change in the physical component of health-related quality of life as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the age-appropriate physical health summary score from PedsQL 4.0 generic core scales for acute illness. PedsQL 4.0 Generic Core Scales and Infant Scales - Acute Version are parent proxy-report scales. The scales range from 0 to 100, with higher scores indicating fewer problems. The physical component of the PedsQL 4.0 Generic Core Scales is composed of one of the four domains: physical functioning. The PedsQL Infant Scales physical component is composed of two of the five domains: physical functioning and physical symptoms.	baseline and 1 year after pediatric intensive care unit discharge
Comparative change in respiratory support	This secondary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. This outcome compares the change in respiratory support as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the respiratory subscale of the functional status scale score. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status with 6 domains. This measure of breathing support will rely on the FSS respiratory domain. The respiratory domain score ranges from 1 (normal) to 5 (very severe dysfunction).	baseline and 1 year after pediatric intensive care unit discharge
Comparative difference in new morbidity	This secondary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. A new morbidity is defined as a change in the functional status scale instrument score by 3 or more, as previously described. This outcome compares the change in the proportion of matched children who acquire a new morbidity as measured at baseline and 12 months after PICU discharge between the two groups. The Functional Status Scale is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction) with total scores ranging from 6 to 30.	baseline and 1 year after pediatric intensive care unit discharge

Collaborators and Investigators

• Sponsor: University of Michigan
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
• Investigators: Principal Investigator: Ryan Barbaro, MD, University of Michigan

Publications and helpful links

General Publications

• Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001 Aug;39(8):800-12. doi: 10.1097/00005650-200108000-00006.
• Fiser DH. Assessing the outcome of pediatric intensive care. J Pediatr. 1992 Jul;121(1):68-74. doi: 10.1016/s0022-3476(05)82544-2.
• Pollack MM, Holubkov R, Glass P, Dean JM, Meert KL, Zimmerman J, Anand KJ, Carcillo J, Newth CJ, Harrison R, Willson DF, Nicholson C; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network. Functional Status Scale: new pediatric outcome measure. Pediatrics. 2009 Jul;124(1):e18-28. doi: 10.1542/peds.2008-1987.
• Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999 Feb;37(2):126-39. doi: 10.1097/00005650-199902000-00003.
• Pollack MM, Holubkov R, Funai T, Berger JT, Clark AE, Meert K, Berg RA, Carcillo J, Wessel DL, Moler F, Dalton H, Newth CJ, Shanley T, Harrison RE, Doctor A, Jenkins TL, Tamburro R, Dean JM; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network. Simultaneous Prediction of New Morbidity, Mortality, and Survival Without New Morbidity From Pediatric Intensive Care: A New Paradigm for Outcomes Assessment. Crit Care Med. 2015 Aug;43(8):1699-709. doi: 10.1097/CCM.0000000000001081.
• Keim G, Watson RS, Thomas NJ, Yehya N. New Morbidity and Discharge Disposition of Pediatric Acute Respiratory Distress Syndrome Survivors. Crit Care Med. 2018 Nov;46(11):1731-1738. doi: 10.1097/CCM.0000000000003341.
• Combes A, Hajage D, Capellier G, Demoule A, Lavoue S, Guervilly C, Da Silva D, Zafrani L, Tirot P, Veber B, Maury E, Levy B, Cohen Y, Richard C, Kalfon P, Bouadma L, Mehdaoui H, Beduneau G, Lebreton G, Brochard L, Ferguson ND, Fan E, Slutsky AS, Brodie D, Mercat A; EOLIA Trial Group, REVA, and ECMONet. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med. 2018 May 24;378(21):1965-1975. doi: 10.1056/NEJMoa1800385.

Study record dates

Study Major Dates

• Study Start (Actual): February 4, 2021
• Primary Completion (Estimated): September 30, 2027
• Study Completion (Estimated): September 30, 2027

Study Registration Dates

• First Submitted: May 18, 2022
• First Submitted That Met QC Criteria: May 18, 2022
• First Posted (Actual): May 24, 2022

Study Record Updates

• Last Update Posted (Actual): December 24, 2025
• Last Update Submitted That Met QC Criteria: December 22, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Quality of Life; Pediatric; ARDS; ECMO; Acute Respiratory Distress Syndrome; Extracorporeal Membrane Oxygenation; ECLS; Extracorporeal Life Support; Functional Status
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Respiration Disorders; Respiratory Distress Syndrome; Therapeutics; Surgical Procedures, Operative; Respiratory Therapy; Extracorporeal Circulation; Extracorporeal Membrane Oxygenation
• Other Study ID Numbers: HUM00173031; R01HL153519-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

It is the National Institutes of Health (NIH) policy that the results and accomplishments of the activities that it funds should be made available to the public (see https://grants.nih.gov/policy/sharing.htm).

After the study is completed, the de-identified, archived data will be transmitted to and stored at the Biologic Specimen and Data Repository Information Coordination Center (BioLINCC), for use by other researchers including those outside of the study. Permission to transmit data to the BioLINCC will be included in the informed consent.

• IPD Sharing Time Frame: Two years after study analysis is complete.
• IPD Sharing Access Criteria: ASCEND investigators will compose the ASCEND steering committee lead by PI Barbaro. Members include Ryan Barbaro, Theodore Iwashyna, Martha Curley, Carol Hodgson, Seth Warschausky and Ben Hansen. The steering committee will be responsible for developing publication procedures and resolving authorship issues.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No